Researchers have uncovered a whole new class of drug compounds with the potential to completely stop the proliferation of specific cancers like leukaemia and liver cancer, and maybe help keep other cancers in remission.
How our cells proliferate from a single egg cell into a precisely formed human composed of trillions of cells is a stupendous feat of genetic regulation.
But it also contains the seeds of cancer when the controls are lost and these cancerous cells can proliferate relentlessly into tumours.
More than two decades ago, a group of scientists began delving into embryonic development to better understand how our cells are directed to make us as we are. It started as curiosity-driven basic research, but has now led to the discovery of a wholly new class of anti-cancer drugs that can stop specific cancer cells from proliferating – putting them to “sleep,” potentially permanently.
The research, just published in scientific journal Nature, has shown the compound works in animal models (mice and zebrafish) by blocking key genes involved in cancers like blood and liver cancers. Unlike chemotherapy and radiotherapy, there is no damage to healthy cells.
CELLS PUT INTO SENESCENCE
“This new class of compounds stop cancer cells dividing and proliferating by switching off their ability to continue the cell cycle,” says joint research leader Associate Professor Anne Voss of the Walter and Eliza Hall Institute of Medical Research and the University of Melbourne.
“The technical term is cell senescence, but essentially the cells are put to sleep. The cancer cells aren’t dead, but they are effectively stopped in their tracks.”
Joint research leader Associate Professor Tim Thomas, also of the Walter and Eliza Hall Institute and University of Melbourne, says that subject to clinical trials the compound has the potential to be “an entirely new weapon for fighting cancer.”
“The compound was well tolerated in our preclinical animal models and is very potent against tumour cells, while appearing not to adversely affect healthy cells,” he says.
At this stage it is unclear what happens to the “sleeping” cancer cells, but the researchers suspect that over time they could be killed and cleared by the immune system.
“We suspect that inducing senescence in the cancer cells will give the immune system more chance to clear these cells because they will eventually be recognised as abnormal,” says Dr Thomas.
FRONTLINE AND CONSOLIDATION TREATMENT
The compound may also work as an adjunct for treatment where a therapy has already been effective in clearing a cancer. By inhibiting the specific processes involved in cancerous cell proliferation the compound could help keep a treated cancer in remission.
“It could be both a frontline treatment for specific cancers and a useful consolidation therapy for some other types of cancer,” says Dr Thomas.
The targeted genes are known as KAT6A and KAT6B and are involved in the growth and development of organisms.
“These genes control cell proliferation and are important in regulating how embryos develop to ensure that everything is in the right place and is the right size. But in some cancers, these are the same genes that will be mutating and driving the growth of cancer.
“So, we always had in the back of our minds that what we were exploring may have implications for treating cancer,” says Dr Thomas.
Indeed, unbeknown to the research team, which also includes Professor Jonathan Baell at the Monash Institute of Pharmaceutical Sciences and Dr Brendon Monahan at the Cancer Therapeutics Cooperative Research Centre, drug companies had been on the same trail but had given up, leading some to believe that these genes were “undruggable.”
It is understandable why. Just working out how to screen the molecules took the team a year of work.
They had to develop a robotic process in which the protein generated by the genes was suspended in a tiny droplet of solution that light would be shone through to monitor the chemical processes they were seeking to inhibit. The process was automated so that 384 molecules could be screened at once on a plate full of tiny wells, each holding a droplet of fluid.
“The research has been a big collaboration and that is most obvious in the screening and testing,” says Dr Voss. “Much of that work was done by the Cancer Therapeutics CRC.”
The next step now is to team up with a pharmaceutical company to pursue clinical trials on patients with the specific cancers that can be targeted through these genes.
“We think these compounds will be effective in treating those cancers where the proliferation of cancer cells through the cell cycle is driven by these KAT6A and KAT6B genes, and if we inhibit these genes it should have a therapeutic effect,” says Dr Thomas.
TARGETING DIFFERENT CANCER PATHWAYS
“For example, we think it will be effective in some blood cancers that block cells from differentiating normally into different cell types.
“In the case of leukaemia, the cancer causes the excessive proliferation of white blood cells, diluting oxygen-carrying red blood cells. Eventually a patient starts to lose their ability to circulate oxygen. We’d hope to be able to stop that from happening.
“I think the future of cancer treatments is very much going to be focused on developing specific treatments like this that target different cancer pathways, rather than a universally applicable therapy across cancer,” says Dr Thomas.
But the source of such treatments will always be knowledge-building, curiosity-driven research.
“We need first of all to understand how the body works if we are to reliably design new therapies, otherwise we are just relying on luck – trying something just to see if it works. Most therapies are derived from knowledge and then experimentation,” says Dr Thomas.
“It can be painstaking and slow, but if you are single-minded enough to keep going the rewards can be potentially life changing for patients.”
Learn more: PUTTING CANCER CELLS TO SLEEP
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Breast cancer survivors honored at Lady Bears game on February 19, 2019 at 1:26 pm
The study was published in the Journal Cancer and reminds women the importance of getting ... some which were currently still undergoing treatment. After being recognized on the floor, the women forme... […]
- Exercise Effects on Depressive Symptoms in Cancer Patients on February 19, 2019 at 1:20 pm
A recent study found that pre-cancer pre-treatment worry was associated with subjective and objective measures of cognitive impairment. The study also found that depression in individuals receiving ch... […]
- First molecular test that selects immunotherapy for kidney cancer on February 19, 2019 at 1:15 pm
Singapore, February 18, 2019 - Immunotherapy drugs such as PD-L1 checkpoint inhibitors represent the front-line treatment for kidney cancer. But immunotherapy is expensive, benefits only a subset of p... […]
- Penn health system faces lawsuit from employee allegedly fired during cancer treatment on February 19, 2019 at 1:12 pm
Former Anthesiologist Technician Kenya Harris is suing on the grounds that the Penn Health System and the Hospital of the University of Pennsylvania discriminated against her on the basis of her cance... […]
- The Search for Targetable Alterations in Pancreatic Cancer on February 19, 2019 at 1:11 pm
There are also other alterations that seem to be predictive for other treatment options that should be explored in the future. And that’s almost 1 out every 5 patients with pancreatic cancer. So it’s ... […]
- Our View: Cancer funding positive step on February 19, 2019 at 12:39 pm
We join all those childhood cancer victims, their parents and families ... laboratory studies that have the greatest potential to quickly deliver new and improved treatments for kids with cancer." Acc... […]
- The Changing Landscape of Pancreatic Cancer Treatment on February 19, 2019 at 12:39 pm
Davendra Sohal, MD, MPH: We’ve certainly made a lot of progress in advanced pancreatic cancer over the last 5 to 7 years or so. It started with FOLFIRINOX, the triple-drug regimen of 5-fluorouracil, i... […]
- Why Do Only Eight Percent Of Cancer Patients In The U.S. Participate In Clinical Trials? on February 19, 2019 at 8:00 am
Moreover, clinical trials offer access to the newest available treatments. So for many patients, participation in a clinical trial can actually represent a desirable choice for the cancer care," said ... […]
- Metastatic Prostate Cancer: Symptoms, Medications and More on February 19, 2019 at 7:12 am
Some patients may need a catheter inserted into their urethra, on a temporary or permanent basis, depending on how they respond to treatment. Stage 4 prostate cancer can also spread to lymph nodes ... […]
via Bing News